Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab + Chemotherapy +/- Tislelizumab in Advanced HER2+ Breast or Gastric/GEJ Cancer
NCT04276493Phase 2Completed
- Sponsor
- BeiGene
- Start
- Mar 2020
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of zanidatamab in breast cancer, gastric cancer (GC), gastroesophageal junction cancer, sponsored by BeiGene. Started Mar 2020; status: completed.
02
Drugs
zanidatamab
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04276493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276493.